Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Mayers Douglas L
   2. Issuer Name and Ticker or Trading Symbol
IDENIX PHARMACEUTICALS INC [IDIX] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
EVP and Chief Medical Officer
(Last)
(First)
(Middle)
IDENIX PHARMACEUTICALS, 320 BENT STREET		 3. Date of Earliest Transaction (Month/Day/Year)
08/05/2014
(Street)

CAMBRIDGE, MA 02141		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $ 8.88 08/05/2014   D     100,000   (1) 01/21/2017 Common Stock 100,000 $ 0 0 D  
Stock Option (Right to Buy) $ 2.41 08/05/2014   D     40,000   (2) 11/08/2017 Common Stock 40,000 $ 0 0 D  
Stock Option (Right to Buy) $ 5.18 08/05/2014   D     80,000   (3) 02/21/2018 Common Stock 80,000 $ 0 0 D  
Stock Option (Right to Buy) $ 5.46 08/05/2014   D     40,000   (4) 02/12/2019 Common Stock 40,000 $ 0 0 D  
Stock Option (Right to Buy) $ 2.96 08/05/2014   D     40,000   (5) 02/09/2020 Common Stock 40,000 $ 0 0 D  
Stock Option (Right to Buy) $ 3.17 08/05/2014   D     60,000   (6) 02/20/2021 Common Stock 60,000 $ 0 0 D  
Stock Option (Right to Buy) $ 12.08 08/05/2014   D     125,000   (7) 02/28/2022 Common Stock 125,000 $ 0 0 D  
Stock Option (Right to Buy) $ 4.65 08/05/2014   D     120,000   (8) 02/19/2023 Common Stock 120,000 $ 0 0 D  
Stock Option (Right to Buy) $ 7.01 08/05/2014   D     100,000   (9) 02/09/2024 Common Stock 100,000 $ 0 0 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Mayers Douglas L
IDENIX PHARMACEUTICALS
320 BENT STREET
CAMBRIDGE, MA 02141		       EVP and Chief Medical Officer  

Signatures

 /s/Maria Stahl, Attorney-in-Fact for Douglas Mayers   08/05/2014
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) These options, which vested in 48 equal monthly installments beginning on January 31, 2007, were cancelled pursuant to the Agreement and Plan of Merger between the Issuer and Merck & Co. Inc. (the "Merger Agreement") in exchange for a cash payment of $15.62 per share, representing the difference between the exercise price of the options and $24.50 per share.
(2) These options, which vested in 48 equal monthly installments beginning on November 30, 2007, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $22.09 per share, representing the difference between the exercise price of the options and $24.50 per share.
(3) These options, which vested in 48 equal monthly installments beginning on February 29, 2008, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $19.32 per share, representing the difference between the exercise price of the options and $24.50 per share.
(4) These options, which vested in 48 equal monthly installments beginning on February 28, 2009, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $19.04 per share, representing the difference between the exercise price of the options and $24.50 per share.
(5) These options, which vested in 48 equal monthly installments beginning on February 28, 2010, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $21.54 per share, representing the difference between the exercise price of the options and $24.50 per share.
(6) These options, which vested in 48 equal monthly installments beginning on February 28, 2011, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $21.33 per share, representing the difference between the exercise price of the options and $24.50 per share.
(7) These options, which vested in 48 equal monthly installments beginning on February 29, 2012, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $12.42 per share, representing the difference between the exercise price of the options and $24.50 per share.
(8) These options, which vested in 48 equal monthly installments beginning on February 28, 2013, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $19.85 per share, representing the difference between the exercise price of the options and $24.50 per share.
(9) These options, which vested in 48 equal monthly installments beginning on February 28, 2014, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $17.49 per share, representing the difference between the exercise price of the options and $24.50 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.